EXTRACTABLES & LEACHABLES SUMMIT 2019

October 15-16, 2019 | Germany

For patient safety reasons a precise knowledge about potential drug impurities is essential. With increasing complexity of container closure systems and single use process equipment the risk of leachables being introduced as real drug impurities increases significantly. Authorities are extensively focusing on determination of leachables present in the real drug matrix which increases the analytical effort and complicates data interpretation.

Spotlight

"A new report published by the Tufts Center for the Study of Drug Development (CSDD) pegs the cost of developing a prescription drug that gains market approval at $2.6 billion, a 145% increase, correcting for inflation, over the estimate the center made in 2003."


OTHER PAST CONFERENCES

European Regulatory Affairs Forum 2022

May 12-13, 2022 | USA

Pharma Education Center warmly invites Regulatory Affairs professionals from pharmaceutical companies to take part to the next “EUROPEAN REGULATORY AFFAIRS FORUM”, which will take place virtually on May 12th and 13th.

Pharmaceutical Mobile Robotics

April 21-22, 2022 | UK

Enabling The Development Of Plug and Play Robotics and Advancing Innovation In QC Labs Of The Future, Pharma Logistics & Automation

SMi's 3rd Annual AI in Drug Discovery Conference

March 14-15, 2022 | UK

SMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference, taking place on the 14th and 15th March 2022 in London, With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning.

1st Annual Psychedelic Therapeutics and Drug Development Conference

May 23-24, 2022 | USA

1st Annual Psychedelic Therapeutics and Drug Development Conference in 2021, we're thrilled to be hosting the 2nd Annual event on May 23-24, 2022 in Washington, DC.

Spotlight

"A new report published by the Tufts Center for the Study of Drug Development (CSDD) pegs the cost of developing a prescription drug that gains market approval at $2.6 billion, a 145% increase, correcting for inflation, over the estimate the center made in 2003."

resources